The discovery and development of GLP-1 receptor agonists for type 2 diabetes and obesity is a bench-to-bedside success story.1 Multiple GLP-1 receptor agonists are now in clinical use, such as ...
Adults with type 1 diabetes who partake in weight cycling and repeatedly lose and regain body weight are more likely to develop diabetic kidney disease, researchers reported in The Journal of Clinical ...